A POTENIALLY YUUGE ADVANCE IN TREATING SCHIZOPHRENIA!!
Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psych... https://t.co/YrZIb8z1RY via @YahooFinance
An integrative framework for perceptual disturbances in psychosis | Nature Reviews Neuroscience. Linking transmitters and biased perception, hoping to understand how one goes from altered dopamine (and possibly other transmitters) to hearing voices https://t.co/L6p4l2NUpY
It was great to celebrate our Conte Center submission last night at Hudson Yards with views on the vessel. Great food, great friends and great hopes 😊!
Dynorphin and the Kappa Opioid Receptor’s Role in the Symptomatology of Schizophrenia: A Review of the Evidence - ScienceDirect: all you ever wanted to know about kappa and schizophrenia, now in Press in Biological Psychiatry!😊😊 https://t.co/qISkh3pDQh
@PhilCorlett1 @stonybrooku@GiorgiaMiche I enjoyed your talk! Always great insights and creative experimental designs! Looking forward to reading about you next steps!
@tomfolanmd The signal in Parkinson disease is very robust. Someone should take on the at risk state in Parkinson, this is where it would be most useful to develop as a bio marker.
Neuromelanin-sensitive MRI identified as a potential biomarker for psychosis, the paper is finally out in PNAS. For those interested in dopamine this is a validation of MRI sequence to image neuromelanin in the nigra, correlates to PET measures of dopamine https://t.co/Agcy7VTnA6